Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The study is a prospective, randomised, controlled, and non-blinded multi-center pilot study to evaluate endocrine efficacy of recombinant luteinizing hormone versus recombinant human chorionic gonadotropin administered during controlled ovarian stimulation for IVF/ICSI in normogonadotrophic women.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Regionshospitalet Viborg, Skive
• Treatments: Chorionic Gonadotropin; Follicle Stimulating Hormone; Hormones

Criteria

Inclusion Criteria:

• Women who plan to undergo IVF or ICSI treatment

• Woman's age > 18 years but ≤ 35 years

• Regular menstrual cycle (25-34 days)

• BMI 18 to 30 inclusive

• Signed patient information and informed consent forms

Exclusion Criteria:

• PCOS

• More than 2 prior IVF/ICSI attempts

• Diabetes mellitus, epilepsy, lever-, kidney-, heart- and metabolism disorders, according to the Investigator's assessment.